Hospital Quality InstituteHospital Quality Institute (HQI)

Help Save Lives!!  Improve the monitoring of patients on opioids to prevent opioid-induced respiratory depression!  Check out this toolkit from the Hospital Quality Institute!

Reducing Harm from Respiratory Depression in Non-ICU Patients through Risk Mitigation and Respiratory Monitoring (November 2017)


Healthcare Technology FoundationHealthcare Technology Foundation (HTF)

HTF has helpful information for patients and their families about alarm sounds they will hear during their hospital stay—please share these brochures!

English   |   Spanish

ISMPISMP Launches First High-Alert Medication Safety Self Assessment


ISMP has introduced a new tool to help hospitals, long-term care facilities, and certain outpatient facilities evaluate their best practices related to high-alert medications, identify opportunities for improvement, and track their experiences over time. The ISMP Medication Safety Self Assessment® for High-Alert Medications focuses on general high-alert medications and 11 specific medication categories--including opioids, insulin, neuromuscular blocking agents, chemotherapy, and moderate and minimal sedation. Participants who submit assessment findings to ISMP anonymously via a secure internet portal will be able to obtain their weighted scores so they can compare themselves to demographically similar organizations. Participation also can help organizations meet requirements for managing high-alert medications from regulatory and accrediting agencies, such as the Centers for Medicare & Medicaid Services and The Joint Commission.

To access the self assessment workbook, go to: http://www.ismp.org/selfassessments/SAHAM.


ANA and FDA Opioid Primer

ANA and FDA present An Opioid Primer: Legislative, Policy, and Practice Implications


Attendees will learn how to:

  1. Identify early and later opioid effects on the brain and illustrate how the brain changes over time with opioid use.
  2. Identify the IOM’s four level barriers to effective pain management and list 2 examples of each level barrier.
  3. Define the Prescription Drug Management Program and its role in state and national drug monitoring efforts.
  4. Describe current drug treatment options and list three barriers to medication assisted treatment programs.

Please join the ANA and FDA for this complimentary webinar.  Sign up here.